What Is CD79b and Its Role in Immunity and Cancer?

CD79b is a protein that sits on the surface of B cells, the white blood cells responsible for producing antibodies. Together with a partner protein called CD79a, it forms the signaling backbone of the B-cell receptor (BCR), the molecular antenna that allows B cells to detect threats and mount an immune response. Without CD79b, B cells cannot develop properly, cannot signal when they encounter a pathogen, and cannot survive. That central role in B-cell biology has made CD79b a focal point in two very different areas of medicine: inherited immune deficiencies where the protein is missing or broken, and B-cell cancers where it is hijacked to fuel uncontrolled growth.

How CD79b Fits Into the B-Cell Receptor

The B-cell receptor is not a single molecule. The part most people picture, the immunoglobulin that recognizes a specific target, cannot signal on its own. It needs a pair of transmembrane proteins, CD79a and CD79b, which sit beside it in the cell membrane and relay the message inside. CD79a and CD79b pair up as a heterodimer, and this pairing is required for the whole complex to reach the cell surface. In cell-line experiments, knocking out either CD79a or CD79b caused complete loss of surface immunoglobulin. The receptor components got stuck in the cell’s internal processing compartments, never maturing or making it to the surface.¹ When researchers re-introduced normal CD79b into those knockout cells, surface expression of both CD79a and immunoglobulin M was restored. A naturally occurring point mutation in CD79b that disrupted its ability to pair with CD79a failed to rescue the receptor, confirming that the physical partnership between the two proteins is non-negotiable.

CD79b first appears on B cells at the pre-B-cell stage, when the cell is still developing in the bone marrow, and it stays on the surface through all subsequent stages of B-cell maturation. It is only downregulated at the very end of the line, just before a B cell differentiates into a plasma cell, the antibody-secreting factory that no longer needs to detect new threats.² That broad and persistent expression across the B-cell lifespan is one of the reasons CD79b has attracted so much attention as a therapeutic target: if you want to hit B cells at most stages of their life, CD79b is reliably there.

Signaling Through the ITAM

The tails of CD79a and CD79b that extend into the cell’s interior each carry a short signaling sequence called an ITAM. When the BCR binds its target, enzymes called kinases add phosphate groups to specific tyrosine residues within these ITAMs. That phosphorylation is the “on” switch for a cascade of downstream signals that tell the B cell to activate, divide, or produce antibodies. Both ITAM tyrosines need to be phosphorylated to fully engage the key downstream kinase Syk, which is the main amplifier of the activation signal.³ Research has shown that phosphorylation of these ITAMs is lopsided in practice, with over 80% of it occurring on the N-terminal tyrosine. This means that at any given moment, most phosphorylated ITAMs carry only a single phosphate and are not in a position to recruit Syk.

This asymmetry turns out to matter. When only one ITAM tyrosine is phosphorylated, the signal shifts away from full B-cell activation and toward an inhibitory circuit involving proteins called SHIP-1 and Dok-1. Researchers studying anergic B cells, B cells that have been rendered unresponsive after chronic stimulation by self-antigens, found that their CD79a ITAMs were biased toward this monophosphorylated state.⁴ In other words, the BCR’s signaling machinery has a built-in dimmer switch. Partial phosphorylation tips the balance toward restraint rather than activation, a mechanism the immune system uses to keep self-reactive B cells in check.

CD79b and BCR Internalization

Beyond relaying signals, CD79b plays a distinct role in pulling the entire BCR off the cell surface after it has been triggered, a process called internalization. This is important because the receptor needs to be brought inside the cell for antigen processing and presentation. A specific tyrosine residue on CD79b, Y195, drives this process. Mutating that residue completely blocks BCR internalization.⁵ That same Y195 residue is the one mutated in many cases of a particular lymphoma subtype, which has implications for both how the cancer behaves and how drugs that target CD79b work.

The internalization function is what makes CD79b attractive as a target for antibody-drug conjugates, drugs that use an antibody to deliver a toxic payload directly into cancer cells. When an antibody-drug conjugate binds CD79b, the protein’s natural tendency to be pulled inside the cell drags the drug in with it. Interestingly, in chronic lymphocytic leukemia (CLL), IgM and CD79b do not travel together during internalization the way they do in normal B cells, suggesting that the coupling between signaling and trafficking can become disorganized in disease.⁶

When CD79b Is Missing Entirely

Inherited mutations that knock out CD79b function cause a severe form of immunodeficiency called autosomal recessive agammaglobulinemia. People with this condition have virtually no circulating B cells and produce little to no antibody, leaving them dangerously vulnerable to infections. A case report documented two siblings with a missense mutation in CD79b who presented with this disease.⁷ Genetic workups of consanguineous families with agammaglobulinemia have confirmed that CD79b mutations sit alongside defects in other pre-BCR components (immunoglobulin heavy chain, CD79a, and others) as established causes.⁸

These cases are rare, but they underscore how essential CD79b is. Without it, B-cell development stalls in the bone marrow and mature B cells never emerge into the bloodstream. Patients typically require lifelong immunoglobulin replacement therapy to survive.

CD79b Mutations in B-Cell Lymphoma

If the complete absence of CD79b shuts B cells down, certain mutations in the protein have the opposite effect: they lock signaling into a permanently “on” state, promoting survival and proliferation even when no genuine antigen is present. This is a hallmark of a subset of diffuse large B-cell lymphoma (DLBCL), the most common aggressive lymphoma. CD79b mutations are found in roughly 16% of the activated B-cell (ABC) subtype of DLBCL, and they frequently co-occur with mutations in a gene called MYD88.⁹ The most common CD79b mutations hit the ITAM tyrosines, particularly Y196, which as noted above is the same residue that controls BCR internalization. By blocking internalization, these mutations keep the receptor on the cell surface longer, amplifying the chronic survival signals that drive the cancer.

The combination of MYD88 and CD79b mutations defines a distinct molecular subgroup now known as MCD-type DLBCL.¹⁰ These two mutations cooperate: MYD88 drives inflammatory signaling through the NF-κB pathway, while CD79b mutations sustain the BCR’s contribution to the same pathway. Together they create a potent pro-survival loop. MCD-type tumors tend to arise in immune-privileged sites like the central nervous system and testes, and the co-mutations are thought to confer tissue-specific homing properties.¹¹ In primary sinonasal DLBCL, for example, the MCD-like subtype defined by MYD88 and/or CD79B mutations was found in over half the cases studied.¹²

CD79b as a Diagnostic Marker

CD79b expression patterns can also help distinguish one B-cell malignancy from another. In CLL, the most common leukemia in adults, CD79b behaves unusually. When researchers tested 40 CLL patients, they found the protein was completely absent in over 40% of cases and expressed at low levels in another 50%.¹³ Since all normal B cells express CD79b, the absence of the protein on a B cell in the bloodstream is a strong indicator that it belongs to the CLL clone. This makes CD79b a useful marker for tracking minimal residual disease, the small numbers of cancer cells that can persist after treatment and eventually cause relapse.

In contrast, most mature B-cell lymphomas, including DLBCL and follicular lymphoma, express CD79b on their surface at readily detectable levels. This difference has practical consequences: it helps pathologists classify ambiguous cases under the microscope and determines which patients are candidates for CD79b-targeted therapies.

Polatuzumab Vedotin, the First CD79b-Targeted Drug

The combination of broad surface expression on B-cell lymphomas and reliable internalization made CD79b a natural target for an antibody-drug conjugate. Polatuzumab vedotin (marketed as Polivy) is a monoclonal antibody directed against CD79b, linked to a potent cell-killing agent called MMAE. When the antibody binds CD79b, the whole complex is pulled into the cell, the linker is cleaved, and MMAE is released inside the cancer cell, where it stops cell division and triggers cell death.¹⁴

The drug was initially approved for relapsed or refractory DLBCL in combination with bendamustine and rituximab. It then moved into the frontline setting based on the phase III POLARIX trial, which compared polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) against the longstanding standard regimen R-CHOP. After about two years of follow-up, roughly 77% of patients in the pola-R-CHP group were alive without disease progression, compared with about 70% in the R-CHOP group.¹⁵ Overall survival at two years was essentially the same between the two arms, but the improvement in progression-free survival was clinically meaningful for a disease where relapse often means a much harder road to cure.¹⁶ Pharmacokinetic analyses from the POLARIX trial confirmed that higher drug exposure correlated with longer progression-free and event-free survival, and that modest increases in exposure did not meaningfully worsen side effects.¹⁷

Real-world pharmacovigilance data from the FDA’s adverse event reporting system has flagged the expected toxicities of the drug, primarily drops in blood cell counts (neutropenia, anemia, thrombocytopenia), febrile neutropenia, peripheral neuropathy, and infections including pneumonia and sepsis.¹⁸ Peripheral neuropathy deserves particular attention since MMAE is known to damage nerve fibers. These side effects are manageable for most patients but require close monitoring.

When the Target Disappears

One concern with any targeted therapy is that cancer cells can evolve to lose the target, rendering the drug ineffective. Early data suggest this can happen with CD79b. In a study of patients who had repeat biopsies after treatment with polatuzumab vedotin, about 13% showed loss of or decreased CD79b expression in their recurrent tumors.¹⁹ That number may seem modest, but it signals that target loss is a real escape route for lymphoma cells, especially in patients who receive CD79b-directed treatment more than once.

CAR-T Cells and Bispecific Antibodies Targeting CD79b

CD79b’s surface presence on most B-cell lymphomas has made it a candidate for newer immunotherapy platforms beyond antibody-drug conjugates. One of the most important is CAR-T cell therapy, in which a patient’s own T cells are engineered to recognize and kill cells bearing a specific target. Most CAR-T products approved so far for lymphoma target CD19, another surface protein on B cells. They have been transformative for many patients, but a significant proportion relapse because their cancer cells lose CD19 expression.

CD79b offers an alternative address on the B-cell surface. Researchers have developed CAR-T cells targeting CD79b that, in laboratory and animal models, killed lymphoma cells effectively, including lymphoma cells that had lost CD19 and would escape CD19-directed therapy.²⁰ Head-to-head comparisons in the lab showed that CD79b-targeting CAR-T cells had comparable tumor-killing ability to CD19-targeting CAR-T cells, and they were effective in multiple aggressive lymphoma models in mice.²¹ Several groups are now developing their own versions of CD79b-directed CARs and comparing different molecular designs to optimize performance.²²

Another approach uses bispecific antibodies, molecules engineered to grab a cancer cell with one arm (via CD79b) and a T cell with the other (via CD3), forcing them together so the T cell can kill the cancer cell. One group constructed a CD79b/CD3 bispecific antibody and paired it with conventional CD19-targeting CAR-T cells. The idea is elegant: if a lymphoma cell loses CD19, the bispecific antibody redirects the same CAR-T cells to attack via CD79b instead. In laboratory and animal models, the combination overcame CD19 escape.²³ These dual-target strategies are still preclinical, but they illustrate how CD79b is becoming a backup plan for the known weakness of CD19-directed therapy.

CD79b in Autoimmune Disease

B cells are not just cancer targets; they are central players in many autoimmune diseases where the immune system attacks the body’s own tissues. Current treatments for conditions like multiple sclerosis often use antibodies against CD20 to deplete B cells entirely, which is effective but blunt. Researchers have explored whether modulating B cells through CD79b could achieve a similar benefit without wholesale depletion. In a mouse model of multiple sclerosis, treatment with an anti-CD79b antibody reduced disease development and progression to a degree comparable to anti-CD20 B-cell depletion. Even a version of the anti-CD79b antibody engineered to lack the ability to kill cells directly still worked, suggesting that the benefit came from quieting B-cell signaling rather than eliminating B cells.²⁴ If this translates to humans, targeting CD79b could offer a gentler way to rein in pathogenic B cells in autoimmune disease while preserving more of the normal immune repertoire.

An Ancient Protein

CD79b is not exclusive to mammals. It has been identified in fish species including rainbow trout and Chinese sucker, where its predicted structure is highly conserved compared to the mammalian version.²⁵ In these fish, CD79b expression changes in response to bacterial, parasitic, and viral infections, indicating that its role in adaptive immunity predates the divergence of fish and land vertebrates by hundreds of millions of years.²⁶ The deep conservation of this protein across such distantly related species suggests that the CD79a/CD79b signaling module was already essential when adaptive immunity first evolved in jawed vertebrates. It also means that certain fish species can serve as informative models for understanding fundamental B-cell biology.